Sinopharm Group Co. Ltd. (SHTDY)
USD 13.79
(0.0%)
USD 13.79
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 263.07 Billion CNY | 3.29% |
| 2022 | 254.7 Billion CNY | 8.04% |
| 2021 | 235.75 Billion CNY | 6.54% |
| 2020 | 221.28 Billion CNY | 14.69% |
| 2019 | 192.94 Billion CNY | 15.2% |
| 2018 | 167.49 Billion CNY | 41.62% |
| 2017 | 118.26 Billion CNY | 4.5% |
| 2016 | 113.17 Billion CNY | 15.95% |
| 2015 | 97.61 Billion CNY | 5.68% |
| 2014 | 92.36 Billion CNY | 20.2% |
| 2013 | 76.84 Billion CNY | 34.56% |
| 2012 | 57.1 Billion CNY | 20.88% |
| 2011 | 47.23 Billion CNY | 73.07% |
| 2010 | 27.29 Billion CNY | 73.08% |
| 2009 | 15.77 Billion CNY | 24.14% |
| 2008 | 12.7 Billion CNY | 8.87% |
| 2007 | 11.66 Billion CNY | 29.65% |
| 2006 | 9 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 307.15 Billion CNY | 5.84% |
| 2024 Q1 | 290.2 Billion CNY | 10.31% |
| 2023 Q3 | 304.01 Billion CNY | -0.19% |
| 2023 FY | 263.07 Billion CNY | 3.29% |
| 2023 Q4 | 263.07 Billion CNY | -13.47% |
| 2023 Q2 | 304.58 Billion CNY | 5.47% |
| 2023 Q1 | 288.79 Billion CNY | 13.38% |
| 2022 Q2 | 267.43 Billion CNY | 3.54% |
| 2022 FY | 254.7 Billion CNY | 8.04% |
| 2022 Q3 | 280.64 Billion CNY | 4.94% |
| 2022 Q4 | 254.7 Billion CNY | -9.24% |
| 2022 Q1 | 258.28 Billion CNY | 9.56% |
| 2021 Q4 | 235.75 Billion CNY | -7.2% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 Q3 | 254.05 Billion CNY | 1.15% |
| 2021 FY | 235.75 Billion CNY | 6.54% |
| 2021 Q2 | 251.15 Billion CNY | 0.0% |
| 2020 Q3 | 237.89 Billion CNY | 6.38% |
| 2020 Q2 | 223.62 Billion CNY | 2.25% |
| 2020 Q1 | 218.71 Billion CNY | 13.35% |
| 2020 FY | 221.28 Billion CNY | 14.69% |
| 2020 Q4 | 221.28 Billion CNY | -6.98% |
| 2019 Q1 | 185.32 Billion CNY | 10.64% |
| 2019 Q2 | 202.8 Billion CNY | 9.43% |
| 2019 Q3 | 213.06 Billion CNY | 5.06% |
| 2019 Q4 | 192.94 Billion CNY | -9.44% |
| 2019 FY | 192.94 Billion CNY | 15.2% |
| 2018 Q2 | 138.38 Billion CNY | 0.0% |
| 2018 Q1 | - CNY | -100.0% |
| 2018 FY | 167.49 Billion CNY | 41.62% |
| 2018 Q4 | 167.49 Billion CNY | 0.0% |
| 2017 Q3 | 132.74 Billion CNY | 5.53% |
| 2017 Q4 | 118.26 Billion CNY | -10.91% |
| 2017 FY | 118.26 Billion CNY | 4.5% |
| 2017 Q2 | 125.79 Billion CNY | 0.0% |
| 2017 Q1 | 125.79 Billion CNY | 11.14% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 113.17 Billion CNY | 0.0% |
| 2016 Q3 | 113.17 Billion CNY | 3.22% |
| 2016 Q2 | 109.65 Billion CNY | 0.0% |
| 2016 FY | 113.17 Billion CNY | 15.95% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 FY | 97.61 Billion CNY | 5.68% |
| 2015 Q3 | 98.55 Billion CNY | 0.17% |
| 2015 Q2 | 98.38 Billion CNY | 0.0% |
| 2015 Q4 | 97.61 Billion CNY | -0.95% |
| 2014 Q1 | 83.14 Billion CNY | 8.2% |
| 2014 Q4 | 92.36 Billion CNY | 0.0% |
| 2014 FY | 92.36 Billion CNY | 20.2% |
| 2014 Q3 | 92.36 Billion CNY | 11.09% |
| 2014 Q2 | 83.14 Billion CNY | 0.0% |
| 2013 Q2 | 70.3 Billion CNY | 0.0% |
| 2013 Q1 | 70.3 Billion CNY | 23.12% |
| 2013 FY | 76.84 Billion CNY | 34.56% |
| 2013 Q4 | 76.84 Billion CNY | 0.0% |
| 2013 Q3 | 76.84 Billion CNY | 9.3% |
| 2012 FY | 57.1 Billion CNY | 20.88% |
| 2012 Q2 | 53.98 Billion CNY | 0.0% |
| 2012 Q4 | 57.1 Billion CNY | 0.0% |
| 2011 FY | 47.23 Billion CNY | 73.07% |
| 2011 Q4 | 47.23 Billion CNY | 0.0% |
| 2011 Q2 | 39.03 Billion CNY | 0.0% |
| 2010 FY | 27.29 Billion CNY | 73.08% |
| 2010 Q4 | 27.29 Billion CNY | 0.0% |
| 2010 Q2 | 21.42 Billion CNY | 0.0% |
| 2009 FY | 15.77 Billion CNY | 24.14% |
| 2009 Q4 | 15.77 Billion CNY | 0.0% |
| 2009 Q2 | 14.8 Billion CNY | 0.0% |
| 2008 Q4 | 12.7 Billion CNY | 0.0% |
| 2008 FY | 12.7 Billion CNY | 8.87% |
| 2007 FY | 11.66 Billion CNY | 29.65% |
| 2006 FY | 9 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| China Medicine Corporation | 21.33 Million USD | -1232944.561% |
| DH Enchantment Inc. | 989.77 Thousand USD | -26579203.541% |
| Exlites Holdings International, Inc. | 33.75 Thousand USD | -779461542.618% |
| Itonis, Inc. | 1.14 Million USD | -22934116.06% |
| One Step Vending Corp. | 465.73 Thousand USD | -56485999.206% |
| MediPal Holdings Corporation | 7.02 Billion USD | -3647.51% |
| PD-Rx Pharmaceuticals, Inc. | 1.69 Million USD | -15500458.507% |
| Pharmagen, Inc. | 8868.81 USD | -2966306529.638% |
| Suzuken Co., Ltd. | 5.36 Billion USD | -4802.122% |